P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal Article
The evolving treatment paradigm of multiple myeloma: From past to present and future.
TL;DR: This review not only summarizes the level of success that has been achieved during the past years but also points to the drawbacks in the current treatment strategies giving emphasize to the potential solutions in the future.
Journal ArticleDOI
Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.
Jacalyn Rosenblatt,Irit Avivi,Baldev Vasir,Tami Katz,Lynne Uhl,Zekui Wu,Poorvi Somaiya,Heidi Mills,Robin Joyce,James D. Levine,Dimitrios Tzachanis,Vassiliki A. Boussiotis,Brett Glotzbecker,Karen Francoeur,Dilani Dombagoda,Michal Tsumer,Lina Bisharat,Nancy Giallombardo,Katharine Conway,Donna Fitzgerald,Rachal Barhad,Paul G. Richardson,Kenneth C. Anderson,Nikhil C. Munshi,Jacob M. Rowe,Donald Kufe,David Avigan +26 more
TL;DR: A cancer vaccine whereby dendritic cells (DCs) are fused with autologous tumor cells is developed, which was associated with suppression of measures of cellular immunity and in vitro T cell responses to tetanus toxoid were blunted in the post-transplant period.
Journal ArticleDOI
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Andrew Yee,Jacob P. Laubach,Erica L. Campagnaro,Brea Lipe,Omar Nadeem,Craig E. Cole,Elizabeth O'Donnell,Robert L. Schlossman,Giada Bianchi,Andrew R. Branagan,Samantha J. Shapiro,Cynthia C. Harrington,Jill N. Burke,Marilyn T. Gammon,Kathleen J. Lively,Cassandra Ann Thorburn,Mason L. Mann,Jens G. Lohr,Paul G. Richardson,Noopur Raje +19 more
TL;DR: Elotuzumab is an approved monoclonal antibody targeting SLAMF7 on NK cells and plasma cells that enhances the activity of lenalidomide and bortezomib in multiple myeloma (MM).
Journal ArticleDOI
CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Sagar Lonial,Paul G. Richardson,Donna E. Reece,Hesham Mohamed,Suresh Shelat,Jesús F. San Miguel +5 more
TL;DR: Nivolumab (nivo), a PD-1 immune cell reprograming agent, is being developed for the treatment of multiple myeloma with a single agent alone or in combination with chemotherapy.
Journal ArticleDOI
A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma Preliminary Safety Data
Peter Gimsing,Torben Plesner,Hareth Nahi,Henk M. Lokhorst,Marie-Louise Valentin,Steen Lisby,Paul G. Richardson +6 more
TL;DR: Daratumumab has a favorable safety profile as monotherapy in patients with multiple myeloma in doses up to and including 2 mg/kg in a classic 3 + 3 dose escalation study.